: a groundbreaking technology that empowers a new generation of manufacturing biotherapeutics
The advantages of cell free protein synthesis (CFPS) over conventional cell-based protein expression have been recognized for decades as it minimizes the time-consuming cloning process and allows expression of protein of interest much faster (4 weeks vs. 6 months) at a lower cost. However, its application has been limited due to the low yield of proteins.
Progeneer’s ANGEL™ platform overcomes the limitations of conventional cell-based protein expression systems (including gene cloning, culture processes) and is a technology that can rapidly synthesize various proteins. First, DNA templates programmed with certain sequences are used to form a function-encoding, free-standing RNA hydrogel. The transcribed RNA self-assembles into an energetically favorable, phase-segregated sub-compartment for localized translation.
This robust, free-standing RNA hydrogel serves as a platform for in-vitro protein expression and enhances productivity by sub-compartmentalization. We were able to produce short peptides, insulin, and biotherapeutics such as rituximab and trastuzumab with a higher yield and the least amount of RNA. Proteins hardly expressed in cell-based system were also efficiently synthesized using ANGEL™ technology. Moreover, these RNA hydrogels can be reused 3-5 times without compromising the protein yield, a desirable platform for continuous protein expression.
Through ANGEL™ platform, Progeneer envisions a new paradigm for manufacturing biotherapeutics and expects to play an important role in tomorrow’s life science industry.
The numerous technological breakthroughs in healthcare have revealed a great deal of inter-individual variation at the molecular level and the diseases processes. The underlying heterogeneity puts forward individualized medicine as the next generation of diagnosis and treatment.
Together with next-generation sequencing (NGS) and Progeneer’s proprietary ANGEL™ technology, we are able to deliver individualized cancer vaccine in 4 weeks.
Experts at Progeneer have extensive experience in analyzing the NGS data and identifying the sequences of the B cell receptors expressed on malignant B cells. Patient-specific antigen is synthesized in 2 weeks through ANGEL™. Our ProLNG vaccine adjuvant can be applied to mount a stronger immune response against the cancer cells by boosting sequence-specific cytotoxic T cell responses. This individualized vaccine ProV can trigger a targeted robust response with the least amount of toxicity.
